Thermo Fisher Scientific is set to acquire the data intelligence company CorEvitas for $912.5 million in cash.
CorEvitas, which is based near Thermo Fisher’s headquarters in Waltham, MA, specializes in real-world evidence generation. The company has 12 registries, including nine in the autoimmune and inflammatory spaces, and boasts more than 400 investigator sites with over 100,000 patients in its system.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters